8dpm › Citations

The evolution and determinants of neutralization of potent head-binding antibodies against Ebola virus.

Yu X, Hastie KM, Davis CW, Avalos RD, Williams D, Parekh D, Hui S, Mann C, Hariharan C, Takada A, Ahmed R, Saphire EO
Cell Rep 42 113366 (2023)
Cited: 4 times
EuropePMC logo PMID: 37938974

Abstract

Monoclonal antibodies against the Ebola virus (EBOV) surface glycoprotein are effective treatments for EBOV disease. Antibodies targeting the EBOV glycoprotein (GP) head epitope have potent neutralization and Fc effector function activity and thus are of high interest as therapeutics and for vaccine design. Here we focus on the head-binding antibodies 1A2 and 1D5, which have been identified previously in a longitudinal study of survivors of EBOV infection. 1A2 and 1D5 have the same heavy- and light-chain germlines despite being isolated from different individuals and at different time points after recovery from infection. Cryoelectron microscopy analysis of each antibody in complex with the EBOV surface GP reveals key amino acid substitutions in 1A2 that contribute to greater affinity, improved neutralization potency, and enhanced breadth as well as two strategies for antibody evolution from a common site.

Articles - 8dpm mentioned but not cited (2)

  1. Local adaptation at higher trophic levels: contrasting hyperparasite-pathogen infection dynamics in the field and laboratory. Parratt SR, Barrès B, Penczykowski RM, Laine AL. Mol Ecol 26 1964-1979 (2017)
  2. The evolution and determinants of neutralization of potent head-binding antibodies against Ebola virus. Yu X, Hastie KM, Davis CW, Avalos RD, Williams D, Parekh D, Hui S, Mann C, Hariharan C, Takada A, Ahmed R, Saphire EO. Cell Rep 42 113366 (2023)


Articles citing this publication (2)

  1. Computational mining of B cell receptor repertoires reveals antigen-specific and convergent responses to Ebola vaccination. Richardson E, Bibi S, McLean F, Schimanski L, Rijal P, Ghraichy M, von Niederhäusern V, Trück J, Clutterbuck EA, O'Connor D, Luhn K, Townsend A, Peters B, Pollard AJ, Deane CM, Kelly DF. Front Immunol 15 1383753 (2024)
  2. Fully human monoclonal antibodies against Ebola virus possess complete protection in a hamster model. Li W, Yang W, Liu X, Zhou W, Wang S, Wang Z, Zhao Y, Feng N, Wang T, Wu M, Ge L, Xia X, Yan F. Emerg Microbes Infect 13 2392651 (2024)


Quick links